AbbVie to acquire Apogee Therapeutics for $10.9B to bolster immunology
Question
AbbVie to acquire Apogee Therapeutics for $10.9B to bolster immunology
Direct answer
M&A activity in the biotech sector driving consolidation and premium valuations for clinical-stage firms. — bullish pressure on APGE via acquisition at $135.11 per share cash premium.
- Original publisher
- Market Ontology
- Evidence through
- 2026-06-23
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “AbbVie to acquire Apogee Therapeutics for $10.9B to bolster immunology”, revision 1, evidence through 2026-06-23. https://marketontology.com/catalysts/2026-06-23/abbvie-to-acquire-apogee-therapeutics-for-10-9b-to-bolster-immunology-7a9326
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| APGE | ▲Bull | Intraday | acquisition at $135.11 per share cash premium | 76 |
AbbVie to acquire Apogee Therapeutics for $10.9B to bolster immunology
M&A activity in the biotech sector driving consolidation and premium valuations for clinical-stage firms. — bullish pressure on APGE via acquisition at $135.11 per share cash premium.
AbbVie paying $135.11 per share in cash.
- SourceAbbVie paying $135.11 per share in cash.
- TransmissionM&A activity in the biotech sector driving consolidation and premium valuations for clinical-stage firms.
- SummaryAbbVie is aggressively filling its post-Humira pipeline. The $135.11 price represents a significant premium for Apogee. Immunology remains the primary M&A battleground for Big Pharma.
- APGEDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- APGE closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- APGE price vs. pre-event level
- APGE volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.